Harbour Biomed Ltd. has received IND clearance by the FDA to initiate clinical trials in the U.S. with HBM-1022, a monoclonal antibody generated from Harbour's integrated G protein-coupled receptor (GPCR) platform. The antibody can enhance antitumor immunity by depleting CCR8 positive regulatory T cells, activating effector T cells.
Pliant Therapeutics Inc. has received FDA clearance of its IND application for PLN-101095, an oral, small-molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.
Sonnet Biotherapeutics Holdings Inc. has completed two IND-enabling toxicology studies in nonhuman primates (NHPs) using its lead bifunctional therapeutic candidate, SON-1210.
Ymmunobio AG has secured ownership of neuronal pentraxin receptor (NPTXR) antibodies after the company signed a transfer ownership agreement with Nagoya University for a license to NPTXR antibodies.
Coeptis Therapeutics Holdings Inc. has entered into a sponsored research agreement with the University of Pittsburgh to advance preclinical development of SNAP-CAR T cells targeting HER2, and to explore opportunities to expand the applicability of SNAP-CAR in oncology.
N6-methyladenosine (m6A) is the most common endogenous modification in eukaryotic RNAs. Researchers are starting to understand the impact of changes in m6A levels on cancer mechanisms, including immune evasion.
Deka Biosciences Inc.'s IND application has been cleared by the FDA allowing the company to proceed with a phase I trial of DK-210 (EGFR) in patients with advanced solid cancer overexpressing epidermal growth factor receptors (EGFR).
Centessa Pharmaceuticals plc has received clearance of its IND application from the FDA to initiate a first-in-human phase I/IIa trial of LB-101 for the treatment of solid tumors.
RSS
